Genedrive Regulatory News (GDR)

7 April 2016

Epistem Holdings Plc ("Epistem" or the "Company")

Senior Executive Incentive Package and Directors' Shareholdings

Following the appointment on 1 March 2016 of David Budd as Chief Executive Officer, and following the publication of the Company's interim results on 31 March 2016, being the end of the close period, the Company has under the Epistem Holdings Plc Share Option Scheme, granted to David Budd on 6 April 2016 options over 244,444 ordinary shares of £0.015p, representing 2.31% of the current issued share capital of the Company. These options are exercisable at 90p per share, being the current middle market price of an Epistem ordinary share. David Budd holds no other options or ordinary shares in the Company.

As compensation for his extra work and commitment as interim Chief Executive Officer between 4 August 2015 to 29 February 2016, the Company has under the Epistem Holdings Plc Share Option Scheme, granted Dr Gilham, Non-Executive Chairman, on 6 April 2016 options over 50,000 ordinary shares of £0.015p, representing 0.47% of the current issued share capital of the Company. These options are exercisable at 278p per share, being a premium of 209% to the current middle market price of an Epistem ordinary share of 90p. Dr Ian Gilham additionally owns a beneficial interest in 20,500 ordinary shares of £0.015p in the Company and holds options over 100,000 ordinary shares of £0.015p in the Company also exercisable at 278p per share.

Epistem today additionally provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.

As a result of the subscription for Partnership Shares and the award of Matching Shares, executive Directors Dr Catherine Booth, John Rylands and Dr Allan Brown each increased their beneficial interests in the Company by 1,962 ordinary shares of 1.5p each. These shares were acquired on 28 October 2015, 27 November 2015, 29 December 2015, 28 January 2016, 29 February 2016 and 28 March 2016 at prices of 140p, 117p, 120p, 115p, 112p and 95p respectively.

Following these transactions, the current beneficial interests of the above executive Directors are set out below:

Ordinary Shares %

Dr Catherine Booth 990,088 9.37%

John Rylands 220,735 2.09%

Dr Allan Brown 25,423 0.24%

Epistem further announces that it was informed on 5 April 2016 that, on that day, Dr Catherine Booth transferred 7,027 ordinary shares of 1.5 pence each to her Self Invested Personal Pension fund at a price of 90p Following this transaction, Dr. Catherine Booth's beneficial interest remains unchanged at 990,088 ordinary shares representing 9.37% of the Company's issued share capital.

For further details please contact:

Epistem Holdings Plc

David Budd: CEO +44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

epistem@consilium-comms.com 

Further details can be found at: www.epistem.co.uk and www.genedrive.com